Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in B-Cell Non-Hodgkin Lymphoma (B-NHL) Patients Mobilized with Granulocyte.

Slides:

Advertisements

Similar presentations

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Advertisements

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1)

Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic.

Improvement of Disease Status Determination and Documentation Pre- and Post- Transplant Michelle Bycko, Crystal Gazaway, Jennifer Holter Chakrabarty,

How to Treat MDS without Stem Cell Transplantation

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report Ivana N.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma Taewoong Choi, Murali K. Kodali, Wen-Kai Weng

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Biology of Blood and Marrow Transplantation

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1 Andrew M. Brunner,

Standardized CD3+ Cell Dose for Allogeneic Peripheral Blood Stem Cell Transplant (PBSCT): An Interim Analysis Muhammad Omer Jamil, MD, Ayman Saad, MD,

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Analysis of the Prognostic Effect of Peripheral Blood Lymphocyte and Monocyte Count after Autologous Hematopoietic Stem Cell Transplant in Refractory/Relapsed.

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children Coco de Koning, Maud Plantinga, Paul Besseling, Jaap Jan Boelens,

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant Maria Gil-Cupello, BA, Gunjan.

Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing.

Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation Jessica T. Stover,

Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.

Biology of Blood and Marrow Transplantation

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Biology of Blood and Marrow Transplantation

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Distinctions Between Effective and Ineffective AML-Specific Autologous Peripheral Blood (PB) Cytotoxic T-Lymphocytes (CTLs) Rohtesh S. Mehta, MD MPH.

Autologous Stem Cell Transplantation (ASCT) Is Effective Therapy for Older Patients with Non-Hodgkin's Lymphoma (NHL) Deepa Jagadeesh, MD, MPH, Lisa.

Autologous Stem Cell Transplant in Patients with Primary Central Nervous System Lymphoma: A Multicenter Analysis From the Sarah Cannon Blood Cancer Network

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+

Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States Song Yao,

Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

Hemophagocytic Lymphohistiocytosis (HLH) after Hematopoietic Stem Cell Transplant (HSCT) or an Impostor: A Word of Caution! Anant Vatsayan, MD, Linda.

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.

Infusion of Autograft Natural Killer Cells/CD14+hla-DRDIM Myeloid-Derived Suppressor Cells Ratio Predicts Survival in Non-Hodgkin Lymphoma Undergoing.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.

Early CD4+ Immune Reconstitution Predicts Probability of Relapse in Pediatric AML after Unrelated Cord Blood Transplantation: Importance of Preventing.

Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation Koji Sasaki, MD, Rima Saliba, PhD, Gary.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Early Results of Phase II Study Using OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HCT-TMA) Samer.

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto)

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Outcomes of Second Unrelated Donor Cord Blood Transplants (UCBT) Performed in Children with Graft Failure of Autologous Recovery Following the First UCBT

Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Blood and Marrow Transplant Handbook

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older.

Evaluation of a Data-Derived Algorithm for Preemptive Use of Plerixafor for Stem Cell Harvest in Patients Eligible for Autologous Stem Cell Transplant.

Koen van Besien, Jeanette Carreras, Philip J. Bierman, Brent R

Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma Tanya M. Wildes, Kristan M. Augustin, Diane.

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study Luis F.

Mammen Chandy Biology of Blood and Marrow Transplantation

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

IL-8 Levels Early after Bone Marrow Transplant are Associated with Later Complications of Stem Cell Transplantation Nikhil Dole, Nathan Luebbering, Nicholas.

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma∗ Theresa Hahn, Philip L. McCarthy,

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Autologous Stem Cell Transplantation for POEMS Syndrome

CD137 Expression Identifies Leukemia Specific CTL after in Vitro Priming of Cord Blood T Cells Previously Expanded By CD3/CD28 Co-Stimulation Jeyaraj.

Presentation transcript:

Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in B-Cell Non-Hodgkin Lymphoma (B-NHL) Patients Mobilized with Granulocyte Colony Stimulating Factor (G-CSF), with or without Plerixafor Pallawi Torka, MD, Paul K. Wallace, PhD, Yali Zhang, MPH, George L. Chen, MD, Christine M. Ho, MD, Sophia R. Balderman, MD, Maureen Ross, MD, PhD, Bruno Paiva, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Philip L. McCarthy, MD, Theresa E. Hahn, PhD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S155-S156 (March 2016) DOI: 10.1016/j.bbmt.2015.11.508 Copyright © 2016 Terms and Conditions

Figure 1 Early ALC recovery is not associated with improved PFS or OS in B-NHL patients in CR pre-AHCT Biology of Blood and Marrow Transplantation 2016 22, S155-S156DOI: (10.1016/j.bbmt.2015.11.508) Copyright © 2016 Terms and Conditions

Figure 2 Higher proportions of CD8+ central memory (CM) T-cells are associated with worse PFS and OS in B-NHL patients in CR pre-AHCT Biology of Blood and Marrow Transplantation 2016 22, S155-S156DOI: (10.1016/j.bbmt.2015.11.508) Copyright © 2016 Terms and Conditions